Simple and Selective Bioanalytical Plasma Sample Extraction Using Oasis® MCX SPE for High Analyte Recovery
Simple and Selective Bioanalytical Plasma Sample Extraction Using Oasis® MCX SPE for High Analyte Recovery
Ce document est une note d’application et ne contient pas de section détaillée concernant l’expérimentation.
Abstract
This application demonstrates the simple and selective bioanalytical plasma sample extraction using mixed-mode ion-exchange solid phase extraction (SPE), requiring no protocol method development, for high extraction MCX SPE recovery of several tyrosine kinase inhibitors (TKI) used in the treatment of leukemia.
Experimental
Figure 1. Demonstration of Oasis MCX SPE bioanalytical extraction performance of several TKI pharmaceuticals, requiring no optimization of the starting protocol, resulting in > 72.6% recovery and matrix effects between -3.8 and -11.0% from plasma.
Results and Discussion
High analyte recovery and selectivity from plasma using Oasis MCX SPE for top-selling small molecule tyrosine kinase inhibitor pharmaceuticals in 2023.1
References
- Williams, RE and Leatherwood HM Top 200 Small Molecule Drugs by Retail Sales in 2023.https://bpb-us-e2.wpmucdn.com/sites.arizona.edu/dist/9/130/files/2024/05/2023Top200SmallMoleculePosterV5.pdf(accessed 21 June 2024).
Featured Products
720008424, July 2024
